An investigation on behalf of investors of AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) shares over potential securities laws violations by AMAG Pharmaceuticals, Inc. and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) concerning whether a series of statements by AMAG Pharmaceuticals, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Waltham MA based AMAG Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. AMAG Pharmaceuticals, Inc. reported that its annual Total Revenue declined from $609.94 million in 2017 to $474 million in 2018 and that its Net Loss declined from $199.22 million in 2017 to $65.76 million in 2018.

On October 29, 2019, AMAG Pharmaceuticals, Inc. announced that the Food and Drug Administrations (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee had voted 16-0 that the Companys confirmatory study, Trial 003, failed to demonstrate the effectiveness of AMAGs Makena product in reducing the risk of preterm births in women with histories of singleton spontaneous preterm birth. The FDA committee also voted 13-3 that the clinical data (Trials 002 and 003) in the Company's application failed to demonstrate substantial evidence of effectiveness.

Shares of AMAG Pharmaceuticals, Inc.(NASDAQ: AMAG) declined from $$13.33 per share on October 29, 2019 to as low as $8.92 per share on November 6, 2019.

Then, on January 9, 2020, AMAG Pharmaceuticals, Inc. disclosed plans to divest its Intrarosa and Vyleesi products in order to lower operating expenses. Concurrently, AMAG announced that William Heiden would step down as AMAGs President and Chief Executive Officer following the appointment of a successor by the Companys Board of Directors.

Shares of AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) declined from $$12.79 per share on December 26, 2019 to as low as $8.99 per share on January 30, 2020.